Amneal Pharmaceuticals (AMRX) announced that the FDA has tentatively approved the company’s abbreviated new drug application for beclomethasone dipropionate HFA inhalation aerosol. The product is the generic equivalent of Qvar inhalation aerosol.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Mycophenolate Pregnancy Registry: Key Insights for Investors
- Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?
- Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
- Amneal treatment of known or suspected cyanide poisoning granted orphan status
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR